Actively Recruiting
Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma
Led by University Hospital, Strasbourg, France · Updated on 2026-01-14
50
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.
CONDITIONS
Official Title
Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 18 years of age
- Diagnosed with metastatic urothelial carcinoma
- Treated with first-line metastatic therapy since October 2024
You will not qualify if you...
- Patient who expressed opposition to participating in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service Oncologie Médicale - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
P
Philippe Barthélémy, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here